Telomere shortening is associated with depression and cognitive impairment in adults

Published Date: 02 Mar 2023

A new research paper titled "The Relationship Between Telomere Shortening in Older Adults and Early Depressive Symptoms and Cognitive Impairment" has been published in Aging.

Read Full News

Latest News



Todays Updates


Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH


Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli


Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD


Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy


FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS


AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo


Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs


Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates


Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH


Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli


Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD


Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy


FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS


AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo


Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs


Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

2.

Why preventive mastectomy isn't offered to everyone at risk

3.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

4.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

5.

AI innovation unlocks non-surgical way to detect brain cancer spread


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot